Purple Biotech Highlights CAPTN-3 Platform at EACR 2025
Ticker: PPBT · Form: 6-K · Filed: Jun 23, 2025 · CIK: 1614744
Sentiment: neutral
Topics: biotech, drug-development, conference
TL;DR
Purple Biotech touts new CAPTN-3 antibody tech at EACR conference.
AI Summary
On June 23, 2025, Purple Biotech Ltd. announced significant advantages of its novel CAPTN-3 tri-specific antibody platform at the EACR 2025 Annual Conference. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel.
Why It Matters
This announcement could signal progress in Purple Biotech's drug development pipeline, potentially impacting the future of its therapeutic candidates.
Risk Assessment
Risk Level: low — The filing is a routine report of a press release announcement and does not contain new financial information or significant corporate events.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- CAPTN-3 (product) — Tri-specific antibody platform
- EACR 2025 Annual Conference (event) — Conference where announcement was made
- Kitov Pharma Ltd. (company) — Former company name
FAQ
What specific advantages of the CAPTN-3 platform were highlighted?
The filing states that significant advantages were announced, but the specific details are not included in this 6-K document, which refers to a press release.
When was the press release issued?
The press release was issued on June 23, 2025.
What is Purple Biotech Ltd.'s principal executive office address?
The address is 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
What is Purple Biotech's SEC file number?
The SEC file number is 001-37643.
What is Purple Biotech's SIC code?
The Standard Industrial Classification (SIC) code is 2834, for Pharmaceutical Preparations.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 23, 2025 regarding PURPLE BIOTECH LTD. (PPBT).